[
  {
    "ts": null,
    "headline": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
    "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
    "url": "https://finnhub.io/api/news?id=5ae6bcf3ecf08e484203067dc82e9fa81f17274cf9de838eafdce8fbbb84aeb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758949163,
      "headline": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
      "id": 136904076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
      "url": "https://finnhub.io/api/news?id=5ae6bcf3ecf08e484203067dc82e9fa81f17274cf9de838eafdce8fbbb84aeb4"
    }
  }
]